CTXR Earnings Date: Dec 22, 2026 (Estimated) — Citius Pharmaceuticals Inc. Common
XNAS · Healthcare · Biotechnology
Updated
When is CTXR's next earnings date?
Citius Pharmaceuticals Inc. Common (CTXR) is expected to report Q4 2026 earnings on Tuesday, December 22, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.41 on revenue of $2.9M.
How did CTXR do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q3 2026), Citius Pharmaceuticals Inc. Common posted EPS of -$0.34 versus the -$0.36 estimate, a beat of 5.6%. Revenue was $1.5M against a $5.5M estimate. The stock's 1-day post-earnings move was -25.6%.
How much does CTXR stock move after earnings?
CTXR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.1% (up or down) in the day after earnings.
About Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q3 2026 | -0.36 | -0.34 | +5.56% | $1.5M | ✅ Beat | -25.62% | -20.57% | -25.87% |
| 2026-05-15 | Q2 2026 | -0.32 | -0.99 | -210.94% | $1.7M | ❌ Miss | -24.76% | +0.10% | -22.66% |
| 2026-02-13 | Q1 2026 | -0.30 | -0.38 | -26.67% | $3.9M | ❌ Miss | -3.55% | -10.64% | +10.99% |
| 2025-12-23 | Q4 2025 | -0.24 | -0.11 | +54.17% | $0 | ✅ Beat | -23.02% | -25.29% | -20.53% |
| 2025-08-12 | Q3 2025 | -0.21 | -0.80 | -280.95% | $0 | ❌ Miss | -1.54% | -5.38% | -7.69% |
| 2025-02-14 | Q1 2025 | -1.25 | -1.30 | -4.00% | $0 | ❌ Miss | -8.18% | -36.43% | -39.03% |
| 2024-12-27 | Q4 2024 | -2.00 | -1.72 | +14.00% | $0 | ✅ Beat | +6.25% | +6.25% | -23.10% |
| 2024-08-12 | Q3 2024 | -1.50 | -1.50 | +0.00% | $0 | ➖ Inline | -11.69% | -7.35% | -23.32% |
Showing last 8 quarters.